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A B S T R A C T
Farming of lumpfish for biological removal of sea lice from farmed Atlantic salmon has expanded rapidly in
Europe and Canada over the last 5–6 years and the lumpfish has become an economically important species.
There are, however, health challenges associated with bacterial diseases. In recent years, there has been an
increase in antibacterial treatments prescribed for this fish species despite a lack of knowledge regarding
pharmacokinetics and effect of treatment with different antibiotics.
The present study examined the uptake, tissue distribution, metabolism and elimination of the antibacterial
agent florfenicol in lumpfish (Cyclopterus lumpus L.) following a single oral administration of 10 mg/kg fish given
in feed. Plasma, head kidney, liver and muscle from six fish were sampled at each time point and analysed by
liquid chromatography/mass spectrometry (LC-MS). Absorption was moderate for this drug characterised by a
calculated peak plasma concentration (Cmax) of 3.55 μg/ml obtained after 21.2 hours (Tmax) and the elimination
halflife (t1/2β) relatively extended in plasma at 30 hours. Area under curve (AUC) and AUC from 0 to 24 hours
(AUC0-24h) were calculated to be 248 and 61 h μg/ml, respectively. Cmax was calculated to 2.99 μg/g in muscle,
2.54 μg/g in liver and 4.70 μg/g in head kidney with corresponding Tmax of 22.1, 26.4 and 19.4 h, respectively.
The main metabolite, florfenicol-amine was found in low concentrations in plasma and all tissues examined. The
minimum inhibition concentrations (MIC) for florfenicol of 28 of Aeromonas salmonicida isolates from diseased
lumpfish ranged from 0.39 to 1.56 μg/ml.
The pharmacokinetical data presented here make an important basis for efficient antibacterial treatment for
lumpfish using florfenicol and for calculation of suitable withdrawal time. Knowledge of florfenicol pharma-
cokinetics, combined with determination of antibiotic resistance among fish pathogenic bacteria and the effect of
antibacterial agents on diseased lumpfish in vivo are important for the welfare of lumpfish and prevention of
resistant bacteria.
1. Introduction
Consumption of antibacterial agents has been low in Norwegian
aquaculture for the last 25 years, (www.fhi.no), largely due to the
widespread use of effective vaccines in salmonid farming. Antibacterial
treatment remains, however, an appropriate tool for control of infection
in marine fish species for which adequate vaccines have not yet been
developed, and there has been an increase in the number of prescrip-
tions registered in recent years for treatment of lumpfish (Grave and
Helgesen, 2018).
The use of cleaner-fish has increased significantly during the last
decade due to increased resistance to therapeutics utilised for salmon
lice (Lepeophtheirus salmonis Krøyer, 1837) removal and a desire for
more environmentally friendly production of Atlantic salmon (Salmo
salar L.). Traditionally, corkwing wrasse (Symphodus melops L.), ballan
wrasse (Labrus bergylta Ascanius, 1767) and goldsinny wrasse
(Ctenolabrus rupestris L.) have been used for this purpose. Lumpfish
(Cyclopterus lumpus L.) have, however, been found to efficiently remove
salmon lice at a wider range of temperatures than the wrasse species
(Imsland et al., 2014; Powell et al., 2018). All lumpfish utilised as
cleaner fish are cultured and production has increased from around 0.4
million fish in 2012 to over 30 million in 2017 (http://www.fiskeridir.
no).
Like other farmed fish, lumpfish are susceptible to various bacterial
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infections e.g. Pseudomonas anguilliseptica, Vibrio ordalii, Vibrio angu-
illarum, Aeromonas salmonicida and Pasteurella sp. (Alarcón et al., 2016;
Gulla and Bornø, 2018; Ellul et al., 2018). Outbreaks of disease often
occur in small fry and after stressful events such as vaccination and sea-
transfer. Mortality levels up to 100% have been reported (Gulla and
Bornø, 2018). Efforts to further develop efficient vaccines for lumpfish
is ongoing. Currently available vaccines, which include V. anguillarum
and atypical A. salmonicida, give high protection against vibriosis and
trials have shown promising results after challenge with atypical A.
salmonicida (Rønneseth et al., 2017; Haugland et al., 2018). Lumpfish
cannot be intraperitoneally vaccinated before they reach 8-10 g and
thus are vulnerable to infections during the early stages of culture.
Today, the two antibacterial agents commercially available as
medicated feeds in Norway are oxolinic acid and florfenicol. Florfenicol
is a synthetic drug with potent activity against several fish pathogenic
bacteria (Fukui et al., 1987; Inglis and Richards, 1991) and is reported
to have good effect on bacterial infections in Atlantic salmon
(Samuelsen et al., 1998), Atlantic cod (Gadus morhua L.) (Samuelsen
and Bergh, 2004; Seljestokken et al., 2006), channel catfish (Ictalurus
punctatus Rafinesque, 1818) (see Gaunt et al., 2010) and Nile tilapia
(Oreochromis niloticus L.) (see Soto et al., 2013). Furthermore, florfe-
nicol possess excellent pharmacokinetic properties in species like
Atlantic salmon (Martinsen et al., 1993; Horsberg et al., 1996) and
Atlantic cod (Samuelsen et al., 2003) although in turbot (Scophthalmus
maximus L.) the drug has a less favourable pharmacokinetic profile (de
Ocenda et al., 2017).
The design of treatment regimens and prediction of probable clin-
ical outcomes represents a practical application of pharmacokinetic
data. To establish a correct dosage regime and thereby promote optimal
use of an antibacterial agent, knowledge of the susceptibility of pa-
thogen to the compound in question and the pharmacokinetic proper-
ties of the drug are required. However, as the properties of antibacterial
agents can vary significantly between fish species, the pharmacoki-
netics of a drug should be investigated in the species in which it is
intended to be used. For food-fish species, information relating to
elimination time is important for the determination of a suitable
withdrawal time.
The aim of this study was to examine the pharmacokinetic proper-
ties of florfenicol in lumpfish following a single oral administration, and
to relate the data to the minimum inhibitory concentration (MIC) va-
lues of florfenicol to A. salmonicida strains, isolated from diseased
lumpfish.
2. Materials and methods
2.1. Experimental fish
Unvaccinated lumpfish (Cyclopterus lumpus L.) were obtained from
Fjord Forsk AS (Sogndal, Norway), transported to the Aquatic and
Industrial Laboratory (ILAB), Bergen, Norway, and kept in flow through
storage tanks (500 l) until the fish reached a mean weight of
113.5 ± 25.0 g and a length of 11.7 ± 1 cm. The seawater had a
salinity of 34‰, a temperature of 12.0 ± 0.5 °C and a flow-rate of
approximately 1000 l/h. The fish were fed a non-medicated ration of
1% body weight per day of dry pellets (Amber Neptun, 1.5 mm pellets,
Skretting, Norway). The fish were fasted for 2 d prior to drug admin-
istration and were not fed the first two days in the experimental period.
The experiment was approved by the Norwegian Food Safety Authority
(ID 10178).
2.2. Administration of feed
The medicated feed used for the per os (p.o.) administration was
Amber Neptun (Skretting) containing 2 g active florfenicol (4 g
Aquaflor premix, Intervet/Schering-Plough Animal Health) per kg feed.
To ease administration, the medicated pellets were diluted 1:1 with
sterile water (Sigma) and homogenized in a GentleMACS Dissociator
(Miltenyi Biotec) using gentleMACS C tubes (Miltenyi Biotec). The paste
was easily administered to the fish via a silicone hose and a syringe.
Prior to drug administration, the fish were weighed and the amount of
feed administered corresponded to a dose of 10mg florfenicol per kg
fish.
2.3. Sampling
Prior to administration of florfenicol-feed, six fish were killed by a
blow to the head and samples of plasma and muscle, head kidney and
liver tissues were obtained. Blood was sampled from the caudal vein
using a 1ml syringe. Plasma was isolated by centrifugation of blood at
approximately 2000 g for 10min. After administration of feed, four
groups of six fish were placed in individual tanks (15 l, with through
flow) following treatment to ensure as accurate sampling as possible.
These four groups were used for the first four samplings. The remaining
fish were kept in a 500 l tank. Samples were taken at 3, 6, 12, 24, 72,
120, 168, 240 and 336 h post administration as described above.
(n=6) All samples were immediately frozen and stored at −20 °C until
analysed.
2.4. Analyses of florfenicol and florfenicol-amine
Tissue samples were homogenized in a Fast Prep-24™5G benchtop
homogenizer (M.P. Biomedicals) using Lysing matrix tubes prefilled
with matrix S metal beads (M.P. Biomedicals). The homogenized tissue
and plasma samples were spiked with internal standards (Florfenikol-d3
and Florfenikol amine-d3; Toronto Research Chemicals, Inc.) and ex-
tracted with a mixture of 49% ethyl acetate, 49% acetonitrile and 2%
ammonia solution (25%) (Xie et al., 2013). The mixtures were vortex-
mixed and centrifuged before the extracts were transferred to a new vial
and concentrated under nitrogen flow at 40 °C. The residues were dis-
solved in water/methanol (80:20) and filtered through a 0.45 μm filter.
Analysis was performed using an Agilent 1290 LC-system (Agilent
Technologies) coupled to an Agilent 6460 triple quadrupole mass
spectrometer (Agilent Technologies). The analytes were separated by a
reverse phase Agilent stable bond C18-column (150mm×2.1mm i.d.,
1.8 μm particle size) (Agilent Technologies) using a 0.4 ml/min flow.
The mobile phase was a mixture of methanol and 0.1% formic acid in
water. Chromatography was performed utilising a stepwise gradient:
0–0.9min, 2% methanol; 1.0–2.0 min, 98% methanol; 2.1–4.0min, 2%
methanol. The instrument was equipped with an electrospray ionization
(ESI) source with polarity switching, operated in a negative mode for
florfenicol and its internal standard, and positive mode for florfenicol
amine and its internal standard. The following source conditions were
used: gas temperature: 200 °C; gas flow: 6 l/min; nebulizer pressure:
35 psi; sheath gas temperature: 350 °C; sheath gas flow: 12 l/min; ca-
pillary voltage: 3600 V (positive mode) and 2500 V (negative mode);
nozzle voltage: 0 V (positive mode) and 100 V (negative mode). The
analytes were monitored using the following transitions: florfenicol,
355,8m/z→185,0m/z (quantifier) and 355,8m/z→119,1m/z (qua-
lifier); florfenicol-d3, 359,0m/z→ 121,1m/z; florfenicol amine,
248m/z→230m/z (quantifier) and 248m/z→ 130,1m/z (qualifier);
florfenicol amine-d3, 251m/z→233,1m/z. Procedural blank, matrix
blank, matrix-matched calibration curve and controls were prepared for
each series. The limit of quantification (LOQ) for florfenicol was de-
termined to 2.0 ng/ml in plasma and 2.0 ng/g in tissue samples. For
florfenicol amine, the LOQ varied from 10 to 20 ng/g in the tissues,
while the LOQ varied from 2.0 to 4.0 ng/ml in plasma. The method was
linear over the range studied for florfenicol amine (LOQ – 400 ng/g).
Florfenicol was linear up to 3000 ng/g; samples with levels above
3000 ng/g were diluted in order to establish a linear calibration curve.
Recovery ranged from 90% to 110%, and relative standard deviation
was< 15%.
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2.5. Pharmacokinetic analysis
Standard pharmacokinetic parameters were calculated using the
computer program PCNONLIN version 4.2 (Statistical Consultants Inc.).
The best fitted models were chosen using Akaike's information criterion
estimation (Yamaoka et al., 1978).
2.6. Bacterial culture
Twenty-eight isolates of A. salmonicida isolated from diseased
lumpfish from different locations in Norway were cultured in tryptic
soy broth (TSB) at 20 °C, 200 rpm until late log phase. The number of
cells were determined using the cell counter CASY Modell TT 150 μm
(Roche Diagnostics) and diluted to a concentration of 5×106 bacteria/
ml.
2.7. Minimum inhibitory concentration (MIC) determinations
The MIC determinations were performed using microtest plate with
96-well with rounded bottom (Sarstedt AG & Co.). A two-fold dilution
of florfenicol (Sigma) in the range of 0.0001–100 μg/ml were per-
formed. Three parallels were performed for each concentration.
Hundred μl of bacterial suspension (5×106 bacteria/ml) were mixed
with 100 μl of antibacterial agents diluted in Tryptone Soya Broth
(TSB). Negative controls containing bacterial suspension, but no anti-
bacterial agents were included for each isolate. The plates were in-
cubated at 20 °C for 48 h. The MICs were determined after visual in-
spection, and given as the concentration where no growth could be
observed.
2.8. Statistical analysis
Analysis of variance (ANOVA) was performed to evaluate the effect
of time using the statistical software package SigmaStat 3.5. Since the
variance was not normally distributed, the P value cut off was set to
0.01 as suggested by Glass et al. (1972). The Holm-Sidak method was
performed for pairwise multiple comparison.
3. Results
The mean florfenicol concentrations versus time in plasma, muscle,
liver and head-kidney tissues are given in Table 1 and Fig. 1. The
highest concentration of florfenicol was detected 24 h post adminis-
tration in plasma and all the tissues. The metabolite florfenicol amine
was found in plasma and all examined organs, although in small
amounts, with the highest concentrations after 24 h (Fig. 2). The
highest concentration of florfenicol amine, 0.21 μg/g, was found in
head-kidney after 24 h (Fig. 2B). The 24 h time point was significantly
higher than the other time points, except for 12 h post oral adminis-
tration (Table 3). For all samples, both the florfenicol and florfenicol-
amine samples, there was a significant effect of time (P < .001)
(Table 3). Pharmacokinetically, the florfenicol plasma data was best
described by a one-compartment open model with first-order input,
first-order output and no lag-time. The values from Table 1 were used to
calculate the pharmacokinetic parameters in PCNONLIN. The peak
plasma concentration (Cmax) was calculated to be 3.55 μg/ml, the time
to peak plasma concentration (Tmax) to be 21.2 h and the elimination
halflife (t½ β) to be 30 h. Area under curve (AUC) and AUC from 0 to
24 h (AUC0–24h) were calculated to be 248 and 61 h μg/ml, respectively.
The pharmacokinetic parameters for plasma, muscle, head kidney and
liver are given in Table 2 and the statistical analyses are summarized in
Table 3.
The susceptibility of florfenicol against 28 isolates of Aeromonas
salmonicida isolated from diseased lumpfish ranged from 0.39 to
1.56 μg/ml and where three isolates had MIC value of 0.39 μg/ml, 14
isolates MIC value 0.78 μg/ml and 11 isolates MIC value 1.56 μg/ml. Ta
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4. Discussion
Knowledge of pharmacokinetics in lumpfish is important. The
number of prescriptions of antibacterials to lumpfish is increasing due
to infection problems, despite the lack of knowledge regarding phar-
macokinetics and efficient treatment regimes for diseased lumpfish. A
number of studies have been published describing the pharmacoki-
netics of florfenicol in fish, but only a few (Martinsen et al., 1993;
Horsberg et al., 1996; Samuelsen et al., 2003; Lim et al., 2010; de
Ocenda et al., 2017) were conducted under conditions comparable to
the present study with regard to external parameters such as salinity
and water temperature. A one-compartment open model with first-
order input, first-order output and no lag-time best described the
plasma data following a single oral administration. This is a pharma-
cokinetic model often used to describe a single oral administration of an
antibacterial agent in fish and has been applied for orally administered
florfenicol in Atlantic cod, Atlantic salmon and turbot (Martinsen et al.,
1993; Horsberg et al., 1996; Samuelsen et al., 2003; de Ocenda et al.,
2017).
Using Tmax as indicator, our results show that florfenicol is rather
slowly absorbed in lumpfish compared to other fish species. While olive
flounder (Paralichthys olivaceus Temminck & Schlegel, 1846), Atlantic
salmon, Atlantic cod and turbot have plasma Tmax values from 4 to
13.8 h, respectively, the plasma Tmax of lumpfish is 21.2 h (Martinsen
et al., 1993; Horsberg et al., 1996; Samuelsen et al., 2003; Lim et al.,
2010; de Ocenda et al., 2017). Following a single oral administration of
10mg/kg florfenicol to Atlantic salmon, Cmax was calculated to 9.1 and
4.0 μg/ml respectively, by Horsberg et al. (1996) and Martinsen et al.
(1993). In Atlantic cod, a similar dose gave Cmax of 10.8 μg/ml
(Samuelsen et al., 2003) whereas a single dose of 20mg/kg gave Cmax of
12.81 in olive flounder (Lim et al., 2010). The Cmax of lumpfish with
3.55 μg/ml is therefore considerably lower than in Atlantic cod and in
Atlantic salmon if compared with the results in Horsberg et al. (1996).
In this study, it was shown that Tmax and Cmax values differed between
lumpfish and other fish species. As lumpfish prefers to attach to the
substrate using their ventrally located suction disk rather than swim
actively, the physiological processes in this species may be slower, and
thereby count for the differences. It is known that lumpfish excrete low
levels of cortisol upon stress compared with cod, salmon and wrasse
(Iversen et al., 2014) and has a different response to stress and external
stimuli compared with salmon and zebrafish (Hale, 2000; Skår et al.,
2017).
Plasma elimination half-lives (t1/2β) of florfenicol vary significantly
in marine fish. Compared with Atlantic salmon (t1/2β of 14.7 and
12.2 h, t=10 °C), the elimination in lumpfish with t1/2β of 30 h at a
temperature of 12 °C can be characterized as slow (Martinsen et al.,
1993; Horsberg et al., 1996; Ocenda et al., 2017). However, in both
Atlantic cod and olive flounder, florfenicol is eliminated at an even
slower rate with t1/2β values of 39 h (t=8 °C) and 49 h (t=18.5 °C),
respectively (Samuelsen et al., 2003; Lim et al., 2010). In lumpfish,
there is a similarity in elimination between plasma and tissues ranging
from 24 h in muscle to 33 in head kidney. In Atlantic cod, on the other
hand, a much larger difference is found in t1/2β values between plasma
(t1/2β=39 h), muscle (t1/2β= 21 h) and liver (t1/2β=20 h).
In this study plasma AUC and AUC0–24h were calculated to be 248
and 61 h μg/ml respectively. Previous publications report only AUC
values and compared to Atlantic salmon with AUC of 140 and 112 h μg/
ml (Martinsen et al., 1993; Horsberg et al., 1996), the AUC of lumpfish
is approximately twice as large. The AUC in Atlantic cod was calculated
to 524 h μg/ml which is twice that found in lumpfish (Samuelsen et al.,
2003). This difference is due, inter alia, to variance in elimination rates
between the species. Based on tissue analysis and the calculated
Fig. 1. Diagrams of uptake and elimination of florfenicol (FF)) at different time point post oral administration of medical feed (10mg/kg). Concentrations of FF in
plasma (A), head kidney (B), liver (C) and muscle (D). Time points are significant different statistically f they do not shear letter. Full statistical analysis is shown in
Table 3.
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pharmacokinetic values shown in Tables 1 and 2 and in Figs. 1 and 2, it
can be concluded that florfenicol is well distributed throughout the
body of lumpfish. Head kidney display the highest concentrations,
followed by muscle and liver.
Florfenicol amine is described as a main metabolite of florfenicol in
Atlantic salmon and was found in higher concentrations than florfenicol
in plasma 48 h after the first administration in a multiple-dose study
(10mg/kg day for 10 consecutive days) (Horsberg et al., 1996). Fol-
lowing a single oral administration of 20mg/kg of florfenicol to the
fresh water fishes rice field eel (Monopterus albus) and Korean catfish
(Silurus asotus), ratios of approximately 4:1 and 3:1 between florfenicol
and florfenicol amine were found at Tmax (Park et al., 2006; Xie et al.,
2013). In Atlantic cod and olive flounder, however, florfenicol amine
was not detected in quantifiable amounts in either plasma or tissues
(Samuelsen et al., 2003; Lim et al., 2010). In this investigation, we
found florfenicol amine in low concentrations, indicating that this
specific metabolic pathway is of minor importance in lumpfish. A
central application of pharmacokinetic and pharmacodynamic data is to
establish appropriate treatment regimens which optimise efficacy and
minimize the opportunity for the development of antimicrobial
resistance.
Traditionally, the clinical significance of pharmacokinetic data was
related to an assumption that the in vivo plasma concentration of the
agent should exceed its minimum inhibitory concentration (MIC) value
for the relevant pathogen by a factor of 3–4 (Stamm, 1989). Later,
Shojaee AliAbadi and Lees (2000) suggested that an optimal dosage
regimen should maintain concentrations at the site of infection in ex-
cess of MIC90 for the entire medication period for bacteriostatic drugs
and bactericidal drugs acting primarily by time-dependant mechanisms
while an Area Under Curve0–24 (AUC0–24)/MIC ratio of at least 100 and
a peak concentration Cmax/MIC ratio of at least 8 should be provided for
bactericidal agents acting mainly by concentration-dependant me-
chanisms (known as PK/PD indices). While the magnitude of PK/PD
indices required for efficacy has been studied in humans and terrestrial
animals no studies of which PK/PD indices to use for the two most used
antibacterials in Norwegian aquaculture, florfenicol and oxolinic acid,
are available (Nightingale et al., 2007). It is appropriate, therefore, to
evaluate efficacy using all three PK/PD indices. In lumpfish, the re-
levant pharmacokinetic values are Cmax of 3.55 μg/ml and AUC0–24 of
61 h μg/ml. The three MIC values of 0.39, 0.78 and 1.56 μg/ml give
Fig. 2. Diagrams of uptake and elimination of Florfenicol amine (FFA) at different time point post oral administration of medical feed (10mg/kg). Concentrations of
FFA in plasma (A), head kidney (B), liver (C) and muscle (D). Time points are significant different statistically f they do not shear letter. Full statistical analysis is
shown in Table 3.
Table 2
Calculated pharmacokinetic parameters for florfenicol in plasma, muscle, head kidney and liver of lumpfish following a single oral administration of 10mg/kg.
Tissue AUC AUC0–24 Cmax Tmax T1/2β
Plasma 248 ± 14 h μg/ml 61 h μg/ml 3.55 ± 0.11 μg/ml 21.2 ± 1.3 h 30 ± 4 h
Muscle 197 ± 14 h μg/g 26 h μg/g 2.99 ± 0.12 μg/g 22.1 ± 1.7 h 24 ± 6 h
Liver 172 ± 14 h μg/g 48 h μg/g 2.54 ± 0.10 μg/g 26.4 ± 1.3 h 33 ± 5 h
Head kidney 338 ± 14 h μg/g 84 h μg/g 4.70 ± 0.11 μg/g 19.4 ± 0.9 h 33 ± 3 h
AUC=Area Under Curve, AUC0–24=Area Under Curve from 0 to 24 h, Cmax=maximum concentration,
Tmax= time to maximum concentration, t1/2β= elimination half-life.
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Cmax/MIC values of 9, 4.5 and 2.3 respectively. Therefore, if the sug-
gestions by Shojaee AliAbadi and Lees (2000) are applied, florfenicol
will, at a dosage of 10mg/kg only give sufficient effect if the fish is
infected by the most sensitive isolates. Corresponding results were ob-
tained using the PK/PD indices AUC0–24/MIC that gave values of 156,
78 and 39 h, respectively. Using the “time above MIC” (T > MIC) as
the PK/PD indices, our investigation shows that florfenicol reached a
Cmax of 3.55 μg/ml and is slowly eliminated with a t1/2β of 30 h. This
indicates that if florfenicol is administered once a day the plasma
concentration will exceed the MIC's for the entire medication period for
all three groups of isolates.
5. Conclusion
Our results indicate that an oral administration of 10mg/kg of
florfenicol will be effective in treating A. salmonicida infection in
lumpfish, at least if caused by the most sensitive strains. The data
generated here is important for development of efficient protocols for
antibacterial treatment, although dose response studies will be needed
for verification of the results and to propose a final recommendation of
dose. Also, the data make the basis for calculation of withdrawal time
and for reducing the risk for development of antimicrobial resistant
bacteria.
Statement of relevance
1) In recent years, there has been an increasing number of prescrip-
tions of antibacterials to lumpfish despite lack of knowledge re-
garding effective treatment regimes.
2) Knowledge of pharmacokinetics combined with determination of
antibiotic resistance among fish pathogenic bacteria and effect of
antibacterial agents on diseased lumpfish is important for the wel-
fare of lumpfish. Additionally, it reduces the risk of development of
drug-resistant bacteria.
Acknowledgements
We would like to thank to Felicia Dawn Couillard for contributing to
the analysis of florfenicol and florfenicol amine. We thank Anita
Rønneseth for giving one of the isolates used in the MIC analysis and
Mark Powell for valuable discussion about the statistics. Funding: The
Norwegian Seafood Research Fund (project 901468, HIW) and
Research Council of Norway (Grant 244148, GTH).
References
Alarcón, M., Gulla, S., Røsæg, M., Rønneseth, A., Wergeland, H., Poppe, T.T., Nilsen, H.,
Colquhoun, D.J., 2016. Pasteurellosis in lumpsucker Cyclopterus lumpus, farmed in
Norway. J. Fish Dis. 39, 489–495.
Ellul, R.M., Walde, C., Haugland, G.T., Wergeland, H., Rønneseth, A., 2018. Pathogenicity
of Pasteurella sp. in lumpsuckers (Cyclopterus lumpus L.). J. Fish Dis. 42 (1), 35–46.
Fukui, H., Fujihara, Y., Kano, T., 1987. In-vitro and in-vivo antibacterial activities of
florfenicol, a new fluorinated analogue of thiamphenicol, against fish pathogens. Fish
Pathol. 22, 201–207.
Gaunt, P.S., Gao, D., Sun, F., Endris, R.G., 2010. Efficacy of florfenicol for the control of
mortality caused by Flavobacterium columnare infection in channel catfish. J. Aquat.
Anim. Health 22, 115–122.
Glass, G.V., Peckham, P.D., Sanders, J.R., 1972. Consequences of failure to meet as-
sumptions underlying the fixed effects analyses of variance and covariance. Rev.
Educ. Res. 42, 237–288.
Grave, K., Helgesen, K.O., 2018. Antibakterielle midler til oppdrettsfisk – rekvirering,
forbruk og diagnoser 2013-2017 (In Norwegian). Rapport 5 – 2018. Norwegian
Veterinary Institute.
Gulla, S., Bornø, G., 2018. The health situation in cleaner fish. In: Hjeltnes, B., Bornø, G.,
Jansen, M.D., Haukaas, A., Walde, C.S.R. (Eds.), In the Health Situation in Norwegian
Aquaculture 2017. Norwegian Veterinary Institute, pp. 97–101.
Hale, M.E., 2000. Fast start behaviors of fish lacking Mauthner neurons. Am. Zool. 40,
1040–1041.
Haugland, G.T., Rønneseth, A., Wergeland, H.I., 2018. Immunology and vaccinology of
lumpfish and wrasse. In: Treasurer, J. (Ed.), Cleaner Fish Biology and Aquaculture
Application. 5M Publishing, pp. 258–280.
Horsberg, T.E., Hoff, K.A., Nordmo, R., 1996. Pharmacokinetics of florfenicol and its
metabolite florfenicol amine in Atlantic salmon. J. Aquat. Anim. Health 8, 292–301.
Imsland, A.K., Reynolds, P., Eliassen, G., Hangstad, T.A., Foss, A., Vikingstad, E.,
Elvegård, T.A., 2014. The use of lumpfish (Cyclopterus lumpus L.) to control sea lice
(Lepeophtheirus salmonis Krøyer) infestations in intensively farmed Atlantic salmon
(Salmo salar L.). Aquaculture 424, 18–23.
Inglis, V., Richards, R.H., 1991. The in-vitro susceptibility of Aeromonas salmonicida and
other fish pathogenic bacteria to 29 antimicrobial agents. J. Fish Dis. 14, 641–650.
Iversen, M.H., Jakobsen, R., Eliassen, R.A., Ottesen, O., 2014. Sedasjon av berggylte og
rognkjeks for å redusere stress og dødelighet (in Norwegian). Nfexpert BIOLOGI-
SVINN 42–46.
Lim, J.-H., Kim, M.-S., Hwang, Y.-H., Song, I.-B., 2010. Plasma and tissue depletion of
florfenicol in flounder (Paralichthys olivaceus) after oral administration. Aquaculture
307, 71–74.
Martinsen, B., Horsberg, T.E., Varma, K.J., Sams, R., 1993. Single dose pharmacokinetic
study of florfenicol in Atlantic salmon (Salmo salar) held in seawater at 11°C.
Aquaculture. 112, 1–11.
Nightingale, C.H., Ambrose, P.G., Drusane, G.L., Murakawa, T., 2007. Antimicrobial
Pharmacodynamics in Theory and Clinical Practice, Second edition. Informa
Healthcare USA, Inc, New York, USA.
de Ocenda, V.R., Almeida-Prieto, S., Luzardo-Álvarez, A., Barja, J.L., Otero-Espinar, F.J.,
Blance-mendez, J., 2017. Pharmacokinetic model of florfenicol in turbot (Scopthalmus
maximus): establishment of optimal dosage and administration in medicated feed. J.
Fish Dis. 40, 411–424.
Park, B.K., Lim, J.H., Kim, M.S., Yun, H.I., 2006. Pharmacokinetics of florfenicol and its
metabolite, florfenicol-amine, in the Korean catfish (Silurus ascotus). J. Vet.
Pharmacol. Ther. 29, 37–40.
Powell, A., Treasurer, J.W., Pooley, C.L., Keay, A.J., Llioyd, R., Imsland, A.K., Garcia de
Leaniz, C., 2018. Use of lumpfish for sea-lice control in salmon farming: challenges
and opportunities. Rev. Aquac. 10, 683–702.
Rønneseth, A., Haugland, G.T., Colquhoun, D.J., Brudal, E., Wergeland, H.I., 2017.
Protection and antibody reactivity following vaccination of lumpfish (Cyclopterus
lumpus L.) against atypical Aeromonas salmonicida. Fish Shellfish Immunol. 64,
383–391.
Samuelsen, O.B., Bergh, Ø., 2004. Efficacy of orally administered florfenicol and oxolinic
acid for the treatment of vibriosis in cod (Gadus morhua). Aquaculture. 235, 27–35.
Samuelsen, O.B., Hjeltnes, B., Glette, J., 1998. Efficacy of orally administered Florfenicol
in the treatment of furunculosis in Atlantic salmon. J. Aquat. Anim. Health 10, 56–61.
Samuelsen, O.B., Bergh, Ø., Ervik, A., 2003. Pharmacokinetics of florfenicol in cod, Gadus
morhua, and in vitro antibacterial activity against Vibrio anguillarum. Dis. Aquat. Org.
56, 127–133.
Seljestokken, B., Bergh, Ø., Melingen, G.O., Rudra, H., Hetlelid Olsen, R., Samuelsen,
O.B., 2006. Treating experimentally induced vibriosis (Listonella anguillarum) in cod
(Gadus morhua L.) with florfenicol. J. Fish Dis. 29, 737–742.
Shojaee AliAbadi, F., Lees, P., 2000. Antibiotic treatment for animals: effect on bacterial
population and dosage regimen optimisation. Int. J. Antimicrob. Agents 14, 307–313.
Skår, M.W., Haugland, G.T., Powell, M.D., Wergeland, H.I., Samuelsen, O.B., 2017.
Table 3
Statistical analyses of the pharmacokinetical data of florfenicol (FF) shown in Fig. 1 and florfenicol-amine (FFA) shown in Fig. 2.*
Sample Sampling time points following oral administration (hours) Significance
0 3 6 12 24 72 120 168 240 336
FF Plasma d c bc ab a c d d d d F9,56= 27.007 (P < .001)
Head kidney e bd bc ac a cd de e e e F9,56= 20.044 (P < .001)
Liver e bcd ab ac a bce de e e e F9,56= 14.176 (P < .001)
Muscle c bc b ab a bc c c c c F9,56= 14.104 (P < .001)
FFA Plasma cd d b abc a ab cd d d d F9,56= 15.512 (P < .001)
Head kidney cdef bfh bd ab a bc beg cdgh cdef cdef F9,56= 11.719 (P < .001)
Liver c bc bc abc a ab c c c c F9,56= 09.800 (P < .001)
Muscle c cd bc ab a abc bd c c c F9,56= 13.934 (P < .001)
* Time points are significant different statistically if they do not shear letter.
K.O. Kverme, et al. Aquaculture 512 (2019) 734279
6
Development of anaesthetic protocols for lumpfish (Cyclopterus lumpus L.): effect of
anaesthetic concentrations, sea water temperature and body weight. PLoS One 12 (7),
e0179344.
Soto, E., Kidd, S., Gaunt, P.S., Endris, R., 2013. Efficacy of florfenicol for the control of
mortality associated with Francisella noatuensis subsp. orientalis in Nile tilapia,
Oreochromis niloticus. J. Fish Dis. 36, 411–418.
Stamm, J.M., 1989. In vitro resistance by fish pathogens to aquacultural antibacterials,
including the quinolones difloxacin (A-56619) and sarafloxacin (A-56620). J. Aquat.
Anim. Health 1, 135–141.
Xie, L.L., Wu, Z.X., Chen, X.X., Li, Q., Yuan, J., Liu, H., Yang, H., 2013. Pharmacokinetics
of florfenicol and its metabolite, florfenicol amine, in rice field eel (Monopterus albus)
after a single-dose intramuscular or oral administration. J. Vet. Pharmacol. Ther. 36,
229–235.
Yamaoka, K., Nakagawa, T., Uno, T., 1978. Application of Akaike’s information criterion
(AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet.
Biopharm. 6, 165–175.
K.O. Kverme, et al. Aquaculture 512 (2019) 734279
7
